Drugs / KLH Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01174082 | Jul 2010 → Feb 2017 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KLH Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01174082 ↗ |
| Modality | Vaccine | “A vaccine will be made of tumor protein taken from your plasma (liquid part of the blood) and KLH (a protein designed to increase the immune response of the vaccine).” NCT01174082 ↗ |
| Route | Subcutaneous | “0.5 cc subcutaneously” NCT01174082 ↗ |